Screener
Celldex Therapeutics CLDX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Cash flows from financing activities: | ||
| Net proceeds from stock issuances | 323,832 | — |
| Proceeds from issuance of stock from employee benefit plans | 1,152 | 265 |
| Net cash provided by financing activities | 324,984 | 265 |
| Net increase (decrease) in cash and cash equivalents | 18,583 | (5,312) |
| Cash and cash equivalents at beginning of period | 28,871 | 28,356 |
| Cash and cash equivalents at end of period | $47,454 | $23,044 |
| Non-cash investing activities |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's financing cash flow?
- Celldex Therapeutics (CLDX) reported financing cash flow of $324.66M in Q2 2026.
- How has Celldex Therapeutics's financing cash flow changed year-over-year?
- Celldex Therapeutics's financing cash flow increased by 515228.6% year-over-year, from $63K to $324.66M.
- What is the long-term trend for Celldex Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Celldex Therapeutics's financing cash flow has grown at a -69.4% compound annual growth rate (CAGR), from $272.4M to $2.39M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Celldex Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude